Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171304 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1SMN1; SMN2GPR52HPGD | |
| SCHEMBL3171296 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1SMN1; SMN2GPR52HPGD | |
| SCHEMBL13527918 | 0.83 | ALDH1A1 (0.39) | KMT2AALDH1A1HPGDMAPTGAA | |
| SCHEMBL22416287 | 0.82 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2GPR52HPGDMAPT | |
| SCHEMBL2513084 | 0.82 | CYP11B1 (0.55) | ALDH1A1HPGDMAPTCYP11B1TSHR | |
| SCHEMBL2513083 | 0.82 | CYP11B1 (0.55) | ALDH1A1HPGDMAPTCYP11B1TSHR | |
| SCHEMBL3570355 | 0.81 | KMT2A (0.50) | KMT2AALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL3570354 | 0.81 | KMT2A (0.50) | KMT2AALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL5318227 | 0.77 | ALDH1A1 (0.58) | KMT2AALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL7383383 | 0.77 | ALDH1A1 (0.58) | KMT2AALDH1A1SMN1; SMN2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KMT2A 1030/4885ALDH1A1 1236/4885SMN1; SMN2 2551/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KMT2A 1030/4885ALDH1A1 1236/4885SMN1; SMN2 2551/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KMT2A 1030/4885ALDH1A1 1236/4885SMN1; SMN2 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.